z-logo
Premium
Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband‐ UVB phototherapy
Author(s) -
Raone Beatrice,
Patrizi Annalisa,
Gurioli Carlotta,
Gazzola Andrea,
Ravaioli Giulia Maria
Publication year - 2018
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/phpp.12382
Subject(s) - medicine , basal cell carcinoma , dermatology , psoriasis , skin cancer , basal cell , incidence (geometry) , vitiligo , melanoma , oncology , cancer , cancer research , physics , optics
Summary Background Narrowband‐ultraviolet B ( NB ‐ UVB ) is widely used for the treatment of several dermatological diseases. A cutaneous carcinogenic effect has been hypothesized, but not proved. Methods We retrospectively reviewed the data of patients treated with NB ‐ UVB between January 1998 and December 2013 at the Dermatology Unit of our University Hospital, to evaluate the cutaneous carcinogenic risk of NB ‐ UVB . Results In all, 375 patients were included, each receiving a mean follow‐up of 6.9 years. Vitiligo and psoriasis were the most common diseases. In total, 19 non‐melanoma skin cancers ( NMSC s) were diagnosed in eight patients, after a mean latency of 5.2 years after the first radiation. No malignant melanoma ( MM ) was observed. The incidence rates of basal cell carcinoma ( BCC ) and squamous cell carcinoma ( SCC ) were 620.2/100 ̇000 p/y and 116.3/100 ̇000 p/y. NMSC s were more frequent in patients affected by psoriasis ( P  = .0232), with older age at the first radiation (mean = 68.8 years, P  = .0001). Conclusion Despite the small number of patients and limited follow‐up, our data suggest that NB ‐ UVB may trigger cutaneous carcinogenesis, mainly in patients at risk for NMSC s, increasing their personal risk for single and multiple neoplasms, usually superficial BCC s. MM risk does not seem to be enhanced.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here